序号 |
标题 |
次数 |
作者 |
发布时间 |
86761 |
7-硝基苯并1,2,3,4-四嗪-1,3-二氧化物(7-NBTDO) |
112 |
WYQ |
2024-11-27 |
86762 |
DOTA-FAPI-04 ,DOTA偶联成纤维细胞活化蛋白抑制剂 |
260 |
kx |
2024-11-27 |
86763 |
446061-19-4 DOTA-p-NH2-Bn-(COOt-Bu)4 DOTA-P-苯-氨基-四叔丁酯 |
113 |
zcy |
2024-11-27 |
86764 |
5-硝基苯并1,2,3,4-四嗪-1,3-二氧化物(5-NBTDO) |
119 |
WYQ |
2024-11-27 |
86765 |
DOTA octreotide,大环配体奥曲肽 |
113 |
zyl |
2024-11-27 |
86766 |
3,6-二胍基-1,2,4,5-四嗪(DGTZ) |
117 |
WYQ |
2024-11-27 |
86767 |
gallium Ga 68-DOTATATE , 镓68偶联DOTATATE螯合物 |
217 |
kx |
2024-11-27 |
86768 |
3,6-二叠氮基-1,2,4,5-四嗪(DIAT) |
111 |
WYQ |
2024-11-27 |
86769 |
DOTA N-hydroxysulfosuccinimide ester 170908-81-3 DOTA-活性酯 |
108 |
zcy |
2024-11-27 |
86770 |
四嗪类高氮含能化合物 |
240 |
WYQ |
2024-11-27 |
86771 |
p-SCN-Bn-DOTA , 2-[(4-异硫氰基苯基)甲基]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 |
103 |
kx |
2024-11-27 |
86772 |
咪唑并四嗪(Imidazopyrazine) |
107 |
WYQ |
2024-11-27 |
86773 |
二聚体多肽,250612-06-7 |
114 |
zyl |
2024-11-27 |
86774 |
DOTA-(t-Butyl)3-PEG5-azide 点击化学试剂 |
117 |
zcy |
2024-11-27 |
86775 |
降冰片烯衍生物(C16-NCA) |
202 |
WYQ |
2024-11-27 |
86776 |
DOTA-CS微球 ,壳聚糖微球上接枝螯合剂1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA) |
94 |
kx |
2024-11-27 |
86777 |
1, 4, 7,10-四氮杂环十二烷-1, 4, 7-三(乙酸)-10-(2-硫乙基)乙酰胺 |
95 |
zcy |
2024-11-27 |
86778 |
3,6-二肼基-1,2,4,5-四嗪(DHT) |
140 |
WYQ |
2024-11-27 |
86779 |
DBCO-SS-PEG-DOTA 二苯并环辛炔-聚乙二醇之四氮杂环十二烷 |
99 |
zyl |
2024-11-27 |
86780 |
3-叠氮基-6-(3,5-二甲基吡唑)-1,2,4,5-四嗪(IADMPT) |
117 |
WYQ |
2024-11-27 |
86781 |
3-肼基-6-(3,5-二甲基吡唑)-1,2,4,5-四嗪(HDMP |
126 |
WYQ |
2024-11-27 |
86782 |
p-NH2-Bn-DOTA(B-200);181065-46-3;基于NOTADOTA定制和偶联 |
91 |
zcy |
2024-11-27 |
86783 |
DOTA-CSar-1 ,DOTA-胆酰肌氨酸 |
153 |
kx |
2024-11-27 |
86784 |
DOTA-MeTz,1610950-41-8,DOTA-甲基四嗪 |
105 |
zyl |
2024-11-27 |
86785 |
四嗪Tetrazine (C18-Tz) |
285 |
WYQ |
2024-11-27 |
86786 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪羟胺盐(TATTN·NH3OH) |
153 |
WYQ |
2024-11-27 |
86787 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪铵盐(TATTN·NH4) |
122 |
WYQ |
2024-11-27 |
86788 |
HA-ASP-CYS-Gd-DOTA ,透明质酸为载体的靶向肿瘤的大分子T1钆基造影剂 |
138 |
kx |
2024-11-27 |
86789 |
CAS:3001301-68-1;DOTA(单酰胺)-OH;DOTA(Monoamides)-OH |
109 |
zcy |
2024-11-27 |
86790 |
DOTA NOC acetate,619300-53-7 |
135 |
zyl |
2024-11-27 |
86791 |
DOTA-SC691-6KL,DOTA偶联卤素取代物 |
118 |
kx |
2024-11-27 |
86792 |
不对称炔丙基取代(+)-Citralis-Propargyl |
107 |
WYQ |
2024-11-27 |
86793 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
85 |
WYQ |
2024-11-27 |
86794 |
CAS:250612-06-7;DOTA-RGD探针二聚体;dota-glu[cyclo(arg-gly-asp-d-phe-lys)]2 |
99 |
zcy |
2024-11-27 |
86795 |
不对称炔丙基取代(-)-AMG 837 |
99 |
WYQ |
2024-11-27 |
86796 |
PEG-G5.NH2-FITC-DOTA(Gd)-Monalizumab/IPH4301纳米探针 |
98 |
kx |
2024-11-27 |
86797 |
不对称炔丙基取代(+)-Phenoxanol-Propargyl |
95 |
WYQ |
2024-11-27 |
86798 |
2125661-62-1;Butyne-DOTA;白色固体 |
87 |
zcy |
2024-11-27 |
86799 |
不对称炔丙基取代(-)-AMG 837 |
138 |
WYQ |
2024-11-27 |
86800 |
DOTA-t-Bu ester , 1-(乙氧羰甲基)-4,7,10-三(叔丁氧羰甲基)-1,4,7,10-四氮杂环十二烷 |
119 |
kx |
2024-11-27 |
86801 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
190 |
zyl |
2024-11-27 |
86802 |
DOTA-Ala-Ala-COOH |
123 |
zyl |
2024-11-27 |
86803 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪肼盐(TATTN·N2H4) 1. 基本信息 |
116 |
WYQ |
2024-11-27 |
86804 |
DOTA-EB-TMTP , 双功能螯合剂DOTA修饰多肽TMTP1 ,DOTA-EB-NVVRQ |
159 |
kx |
2024-11-27 |
86805 |
3-硝铵基-6-(1H-四唑-5-基)-[1,2,4]三唑[4,3-b][1,2,4,5]四嗪(TATTN) 1. 基本信息 |
125 |
WYQ |
2024-11-27 |